Update on the role of rituximab in kidney diseases and transplant

Expert Opinion on Biological Therapy

Volumn 12, Issue 2, 2012, Pages 223-233

  Ramanath, Vinayak ^a   Nistala, Ravi ^a   Chaudhary, Kunal ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Glomerulonephritis; Kidney transplant; Rituximab

Indexed keywords

ALLOANTIBODY; AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PEGINTERFERON; PREDNISOLONE; RIBAVIRIN; RITUXIMAB; STEROID;

ANCA ASSOCIATED VASCULITIS; ANTIBODY PRODUCTION; B LYMPHOCYTE; CRYOGLOBULINEMIA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE INFERTILITY; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; KIDNEY DISEASE; KIDNEY GRAFT; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NEOPLASM; NEPHROTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION;

EID: 84855642809     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.646984     Document Type: Review

References (82)

1. Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006;2:221-30 (Pubitemid 43787288)
2. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7 (3):711-17
3. Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 1989;264:11282-7 (Pubitemid 19168862)
4. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1984;63:1424-33 (Pubitemid 14120390)
5. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985;135:973-9 (Pubitemid 16242785)
6. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti- CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584-91 (Pubitemid 17022032)
7. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6 (Pubitemid 30208162)
8. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDECC2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66 (Pubitemid 24317376)
9. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008;87:345-64
10. Shlomchik MJ, Madaio MP, Ni D, et al. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994;180:1295-306 (Pubitemid 24289603)
11. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6
12. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005;238:67-75
13. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11
14. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5 (Pubitemid 41742472)
15. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-7 (Pubitemid 41527814)
16. Kessel A, Rosner I, Toubi E. Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 2008;34:74-9
17. van den Hoogen MW, Hilbrands LB. Use of monoclonal antibodies in renal transplantation. Immunother 2011;3:871-80
18. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73
19. Tavazzi E, White MK, Khalili K. Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol 2011;published online 20 September 2011; doi: 10.1002/rmv.710
20. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood 2009;113:4834-40
21. Thaunat O, Morelon E, Defrance T. Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 2010;116:515-21
22. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009;18:767-76
23. Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol 2011;40:159-69
24. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 2006;8 (3):R83
25. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum 2009;61:482-7
26. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
27. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 2010;70:529-40
28. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2458-66
29. Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol 2010;11:published online 24 June 2010; doi:10.1186/1471-2369-11-12
30. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20
31. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32
32. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2011; published online 25 May 2011; doi: 10.1093/rheumatology/ker150
33. Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995;88:115-26
34. Garini G, Allegri L, Lannuzzella F, et al. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007;78:51-9
35. Zaja F, De Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002;46:2252-4; author reply 2254-2255
36. Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008;34:111-17
37. Zaja F, Russo D, Fuga G, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999;84:1157-8 (Pubitemid 30016593)
38. Cacoub P, Delluc A, Saadoun D, et al Anti-CD 20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008 67 283-7 (Pubitemid 351281259)
39. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26 (Pubitemid 36857852)
40. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferonalpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116 (3):326-34; quiz 504-505
41. Sugiura H, Takei T, Itabashi M, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 2011;117:c98-c105
42. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 2003;;14:1851-7 (Pubitemid 36750480)
43. Bomback AS, Derebail VK, McGregor JG, et al. Rituximab therapy for membranous nephropathy: A systematic review. Clin J Am Soc Nephrol 2009;4:734-44
44. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 2010;5:2188-98
45. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008;73:117-25 (Pubitemid 350273646)
46. Cravedi P, Sghirlanzoni MC, Marasa M, et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study. Am J Nephrol 2011;33:461-8
47. Cravedi P, Ruggenenti P, Remuzzi G. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J Am Soc Nephrol 2011;22:1400-2
48. Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543-50
49. van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011;26:881-92
50. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978;13:159-65
51. Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988; 113:996-1001 (Pubitemid 19014247)
52. Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr Nephrol 2008;23:1269-79
53. Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009;24:1321-8
54. Prytula A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010;25:461-8
55. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007;356:2751-2 (Pubitemid 47001064)
56. Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010;5:2207-12
57. Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant 2010;14:314-25
58. Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009;87:1232-9
59. Evans RW, Manninen DL, Garrison LP, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9 (Pubitemid 15174151)
60. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993;270:1339-43 (Pubitemid 23267894)
61. Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011;91:853-7
62. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996-1001 (Pubitemid 38745599)
63. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053-7
64. Paul LC, van Es LA, Riviere GB, et al. Blood group B antigen on renal endothelium as the target for rejection in an ABO-incompatible recipient. Transplantation 1978;26:268-71
65. Imamura R, Ishiguro S, Shi Y, et al. ABO-incompatible kidney transplantation with anti-CD20 monoclonal antibodies, intravenous immunoglobulin and plasmapheresis without splenectomy: A case report. Xenotransplantation 2006;13:133-5
66. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004;4:1315-22 (Pubitemid 39013579)
67. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005;5:145-8 (Pubitemid 40095139)
68. Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009;22:447-54
69. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003;3:1488-500 (Pubitemid 37541506)
70. Cho YW, Cecka JM. Crossmatch tests-an analysis of UNOS data from 1991-2000. Clin Transpl 2001;237-46
71. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-51 (Pubitemid 352008439)
72. Kozlowski T, Andreoni K Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant 2011 16 19-25
73. Lai CH, Cao K, Ong G, et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011;92:48-53
74. Tyden G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009;87 (9):1325-9
75. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009;360:2683-5
76. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011;11:1359-67
77. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010;89:1403-10
78. Mulley WR, Hudson FJ, Tait BD, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009;87:286-9
79. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990;323:1767-9
80. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-6 (Pubitemid 43923950)
81. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005;80:1692-8 (Pubitemid 43053993)
82. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038-46